• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ADAG

ADAG

Adagene Inc.

NASDAQHealthcareBiotechnologyCN

USD3.46

+0.07 (+2.06%)

Rating:C

Company Profile

CEO

Peter Luo

IPO Date

2021-02-09

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

CN

Market Metrics

Open

$3.33

Prev. Close

$3.39

Day Low

$3.31

Day High

$3.49

52W Low

$1.30

52W High

$4.75

Market Cap

$0.13B

Volume

0.05M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

41.3%

Avg Negative

1.1%

Avg Neutral

57.7%

News Feed

Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors

Benzinga·7/22/2021·↑ positive

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

GlobeNewsWire·7/22/2021·↑ positive

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

GlobeNewsWire·7/7/2021·↑ positive

Adagene Announces Inclusion in FTSE Russell Indexes

GlobeNewsWire·6/16/2021·↑ positive

Adagene to Present at Upcoming Investor Conferences

GlobeNewsWire·5/25/2021·↑ positive

Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting

GlobeNewsWire·5/19/2021·↑ positive

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021

GlobeNewsWire·4/13/2021·↑ positive

Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates

GlobeNewsWire·3/31/2021·↑ positive

Adagene Announces Clinical Advancement for ADG116

GlobeNewsWire·3/29/2021·↑ positive

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

GlobeNewsWire·3/16/2021·↑ positive